Agamree (Vamorolone) Patent Expiration, LOE Window & CMS Spending

Agamree (Vamorolone) by Catalyst: FDA Orange Book core substance LOE 2040-07-16, 0 AB generics, $31.9M 2024 CMS Part D & Medicaid spend, and $9,500 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorCatalyst
FDA Application & PathwayN215239 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2040-07-16
Last Listed Patent or Exclusivity Date2040-07-16
Orange Book Patents (*PED Extensions)7 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$31.9M
2024 Medicare Part D Spend$699K
2024 Medicaid Spend$31.2M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($9,500 intro WAC)